ArticleHeart and vessels2016
Intramyocardial delivery of VEGF165 via a novel biodegradable hydrogel induces angiogenesis and improves cardiac function after rat myocardial infarction.
Article in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Injectable Thermoresponsive Hydrogels for Localized Drug Delivery: Mechanisms, In Vivo Evidence and Translational Challenges.Journal of functional biomaterials · 2026Review
- Natural Polymers in Tissue Engineering and Regeneration: Material-Cell Mechanotransduction, Biofabrication Strategies, and Clinical Translation.Biomedicines · 2026Review
- NicOPURE: nickless RNA circularization and one-step purification with engineered group II introns and cyclizing UTRs.Nucleic acids research · 2025Article
- Developments in Extracellular Matrix-Based Angiogenesis Therapy for Ischemic Heart Disease: A Review of Current Strategies, Methodologies and Future Directions.Biotech (Basel (Switzerland)) · 2025Review
- Targeting the Notch signaling pathway: molecular mechanisms and therapeutic strategies for cardiac repair after myocardial infarction.Frontiers in cardiovascular medicine · 2025Review
- Hydrogels for Cardio and Vascular Tissue Repair and Regeneration.Gels (Basel, Switzerland) · 2024Review
- Therapeutic angiogenesis based on injectable hydrogel for protein delivery in ischemic heart disease.iScience · 2023Review
- A deep dive into the darning effects of biomaterials in infarct myocardium: current advances and future perspectives.Heart failure reviews · 2022Review
- Endothelial Transient Receptor Potential Canonical Channel Regulates Angiogenesis and Promotes Recovery After Myocardial Infarction.Journal of the American Heart Association · 2022Article
- Therapeutic Acellular Scaffolds for Limiting Left Ventricular Remodelling-Current Status and Future Directions.International journal of molecular sciences · 2021Review
- VEGF121 Mediates Post-Hypoxia Cardioprotective Effects Via CaSR and Mitochondria-Dependent Protease Pathway.Arquivos brasileiros de cardiologia · 2021Article
- Biologics and their delivery systems: Trends in myocardial infarction.Advanced drug delivery reviews · 2021Review
- Intra-myocardial Delivery of a Novel Thermosensitive Hydrogel Inhibits Post-infarct Heart Failure After Degradation in Rat.Journal of cardiovascular translational research · 2020Article
- Pharmacokinetic Advantage of ASD Device Promote Drug Absorption through the Epicardium.Pharmaceutical research · 2020Article
- Microneedle-mediated gene delivery for the treatment of ischemic myocardial disease.Science advances · 2020Article
- Injectable Hydrogel-Based Nanocomposites for Cardiovascular Diseases.Frontiers in bioengineering and biotechnology · 2020Review
- Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis.Acta pharmacologica Sinica · 2019Article
- Synergistic effects of laminin-1 peptides, VEGF and FGF9 on salivary gland regeneration.Acta biomaterialia · 2019Article
- Approaches to therapeutic angiogenesis for ischemic heart disease.Journal of molecular medicine (Berlin, Germany) · 2019Review
- Quantitative assessment of salvaged myocardial zone and intramyocardial hemorrhage using non-contrast faster T2 mapping in a rat model by 7T MRI.Experimental and therapeutic medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor (VEGF), an independent mitogen, has been reported to induce angiogenesis and thus attenuates the damage induced by myocardial infarction (MI). VEGF165 is the most abundant and predominant isoform of VEGF. This study investigates whether this effect could be strengthened by local intramyocardial injection of VEGF165 along with a novel biodegradable Dex-PCL-HEMA/PNIPAAm hydrogel and ascertains its possible mechanism of action. Rat models of myocardial infarction were induced by coronary artery ligation. Phosphate-buffered saline (PBS group), Dex-PCL-HEMA/PNIPAAm hydrogel (Gel group), phosphate-buffered saline containing VEGF165 (VP group), and hydrogel containing VEGF165 (VPG group) were injected into a peri-infarcted area of cardiac tissue immediately after myocardial infarction, respectively. The sham group was thoracic but without myocardial infarction. The injection of VEGF165 along with a hydrogel induced angiogenesis, reduced collagen content and MI area, inhibited cell apoptosis, increased the level of VEGF165 protein and the expression of flk-1 and flt-1, and improved cardiac function compared with the injection of either alone after MI in rats. The results suggest that injection of VEGF165 along with a hydrogel acquires more cardioprotective effects than either alone in rat with MI by sustained release of VEGF165, then may enhance the feedback between VEGF and its receptors flk-1 and flt-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.